Skip to main content
. Author manuscript; available in PMC: 2021 Jun 11.
Published in final edited form as: Nat Med. 2020 Jul 10;26(9):1422–1427. doi: 10.1038/s41591-020-0998-x

Fig. 4. Neutralizing activity of potent mAbs against SARS-CoV-2 and SARS-CoV.

Fig. 4.

a. Dose-response neutralization of SARS-CoV-2 luciferase reporter virus by representative potently neutralizing mAbs that were identified by rapid RTCA screening assay. IC50 values are indicated for each mAb. Data shown are the mean of two technical replicates from one of two independent experiments, and error bars denote the standard deviation for each point.

b. Neutralization of SARS-CoV-luciferase reporter virus by cross-reactive mAbs COV2-2678 and COV2-2514. IC50 values are indicated for each mAb, with “-” indicating mAbs that did not neutralize SARS-CoV. Data shown are the mean ± SD of two technical replicates from one of two independent experiments.